Open AccessCandidate molecules as diagnostic biomarker for human uterine mesenchymal tumors
Author(s) -
T Hayashi,
Kenji Sano,
Tohru Ichimura,
Gökçe Gür,
Pnina Yaish,
Dorit Zharhary,
Y Kanai,
Susumu Tonegawa,
Nobuo Yaegashi,
Ikuo Konishi
Publication year - 2020
Publication title -
annals of cytology and pathology
Language(s) - English
Resource type - Journals
ISSN - 2640-7809
DOI - 10.17352/acp.000016
Subject(s) - leiomyosarcoma , biomarker , stage (stratigraphy) , oncology , medicine , mesenchymal stem cell , cancer , pathology , cancer research , biology , paleontology , biochemistry
Unfortunately, uterine leiomyosarcoma still has a poor prognosis. The National Cancer Institute reported that the median overall survival (mOS) at stage I to stage IV of leiomyosarcoma was 31 months.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom